secwatch.observer — SEC 8-K summary
======================================

Issuer:     BiomX Inc. (PHGE)
CIK:        0001739174
Form:       8-K
Filed at:   2025-03-25T23:59:59+00:00
Accession:  0001013762-25-001826
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BiomX reports FY2024 results, $12M financing, Phase 2 DFO readout imminent
--------------------------------------------------------------------------

- Phase 2 topline results for BX211 in diabetic foot osteomyelitis expected by end of March 2025.
- February 2025 financing raised ~$12M gross proceeds to support BX004 Phase 2b readout in Q1 2026.
- Cash and restricted cash $18.0M at Dec 31, 2024; plus $12M raised in Feb 2025; runway into Q1 2026.
- FY2024 net loss $17.7M (vs $26.2M); R&D expenses $24.7M; impairments on goodwill, IPR&D, and assets.
- Non-dilutive funding from DHA for BX211 totaled $36.8M to date; manufacturing delays for BX004 resolved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739174/000101376225001826/0001013762-25-001826-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739174/000101376225001826/ea0235496-8k_biomx.htm
  HTML page:      https://secwatch.observer/filing/0001013762-25-001826

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer